Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943524 | 1.00 | LMNA (0.33) | LMNATRPA1ADRB2ADRB1ADRB3 | |
| SCHEMBL9943652 | 1.00 | LMNA (0.33) | LMNATRPA1ADRB2ADRB1ADRB3 | |
| SCHEMBL9943817 | 0.87 | LMNA (0.33) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943667 | 0.87 | LMNA (0.33) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943669 | 0.87 | LMNA (0.33) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943640 | 0.82 | LMNA (0.37) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943463 | 0.82 | LMNA (0.37) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943465 | 0.82 | LMNA (0.37) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943432 | 0.81 | ADRB2 (0.36) | LMNAADRB2ADRB1ADRB3BTN3A1 | |
| SCHEMBL9943433 | 0.81 | ADRB2 (0.36) | LMNAADRB2ADRB1ADRB3BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465847-B1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2016-10-12 | — | — | EP | disclosed |
| US-8623855-B2 | Azetidinone compounds and medical use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-01-07 | — | — | US | disclosed |
| US-20120208994-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2012-08-16 | — | — | US | disclosed |
| EP-2465847-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208994-A1 | AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF | CYP46A1, APOB, CETP | LMNA 1008/4885TRPA1 4031/4885ADRB2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.